CONNEQT Lodges FDA Pre-Submission for SphygmoCor Cloud
Filed with ASX · · 5 pages · English
Summary by 6ix AI
CONNEQT Health Limited has lodged an FDA Pre-Submission for its SphygmoCor Cloud platform, which aims to transition its arterial health analytics from hardware to a cloud-based software model. This move is expected to create new commercial opportunities, including Biomarker-as-a-Service and integration with third-party devices. If cleared, SphygmoCor Cloud would be the company's sixth FDA-cleared product, enhancing its position in the cardiovascular health market. The regulatory timeline indicates that FDA feedback is anticipated in the near future, with a formal submission planned shortly thereafter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Conneqt Health
- CONNEQT Completes $5.5m Placement
- Half Yearly Report and Accounts
- December Quarterly Appendix 4C
- December Quarterly Activities Report
- CONNEQT Completes $3.1m Institutional Placement
Later from Conneqt Health
- CQT Announces SPP Launch, Booklet & Timetable
- CQT Expands US Distribution Through Blueprint Agreement
- September Quarterly Appendix 4C
- September Quarterly Activities Report
Follow Conneqt Health into a list and get an email when it puts out news.
Follow Conneqt Health